Original ImageHover Image
Original ImageHover Image

The Platform Trial In COVID-19 Vaccine priming and BOOsting (PICOBOO) is a multi-arm, multi-domain, Bayesian randomised controlled adaptive platform trial designed to evaluate the impact of different COVID-19 booster vaccines on the immune system.

What is an adaptive trial?

Adaptive trials utilise innovative design features that seek to improve clinical trial efficiency. They may have benefits of flexibility and efficiency over conventional trials. An adaptive platform trial (APT) studies multiple interventions for a single disease or condition within a single trial platform. Intervention arms (e.g. new vaccines) may be added or removed depending on pre-specified rules. APTdesign features allow new knowledge to be generated efficiently and participants stand to benefit directly from accumulating trial data. APTs may also be more cost effective than conventional trial designs.

To read more about the benefits of adaptive clinical trials and how they work, please visit the Adaptive Health Intelligence website.


Adaptive: An adaptive trial is a type of study design where researchers can modify certain aspects of the trial after it starts without threatening the integrity of the trial. This includes the introduction of new vaccines for evaluation as they become available for use.

Randomised Control Trial: In this type of trial, participants are randomly assigned to study Intervention. In this study, participants will receive one type of booster vaccine. This helps ensure that the results are not influenced by any factors other than the intervention under study.